These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23769852)

  • 21. Ischaemia versus bleeding: the art of clinical decision-making.
    Stone GW
    Lancet; 2009 Feb; 373(9665):695-6. PubMed ID: 19249613
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart Advis; 2010 May; 13(5):6. PubMed ID: 22816152
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prasugrel or clopidogrel in patients with coronary intervention].
    Schrör K
    Internist (Berl); 2009 Nov; 50(11):1293-6. PubMed ID: 19830398
    [No Abstract]   [Full Text] [Related]  

  • 25. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
    Greenhalgh J; Bagust A; Boland A; Saborido CM; Fleeman N; McLeod C; Dundar Y; Dickson R; Proudlove C; Kolamunnage-Dona R; Fisher M
    Health Technol Assess; 2010 May; 14 Suppl 1():31-8. PubMed ID: 20507801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute coronary syndromes: identifying the appropriate patient for prasugrel.
    Stephens JC; Askari AT
    Postgrad Med; 2012 Mar; 124(2):16-28. PubMed ID: 22437212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of prasugrel in acute coronary syndrome patients.
    Nanau RM; Delzor F; Neuman MG
    Clin Biochem; 2014 May; 47(7-8):516-28. PubMed ID: 24657510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the metabolism of clopidogrel and prasugrel.
    Laizure SC; Parker RB
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1417-24. PubMed ID: 20839914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017
    [No Abstract]   [Full Text] [Related]  

  • 31. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
    Serebruany VL; Alberts MJ; Hanley DF
    Cerebrovasc Dis; 2008; 26(1):93-4. PubMed ID: 18547948
    [No Abstract]   [Full Text] [Related]  

  • 32. Prasugrel (Effient) vs. clopidogrel (Plavix).
    Med Lett Drugs Ther; 2009 Sep; 51(1320):69-70. PubMed ID: 19738549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prasugrel for the treatment of patients with acute coronary syndrome.
    Marzot F; Pengo V
    Vasc Health Risk Manag; 2009; 5(1):321-4. PubMed ID: 19436677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel.
    Devabhakthuni S; Seybert AL
    Crit Care Nurse; 2011 Feb; 31(1):51-63. PubMed ID: 20592188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
    MMW Fortschr Med; 2009 Sep; 151(36):50. PubMed ID: 19813542
    [No Abstract]   [Full Text] [Related]  

  • 38. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 39. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of a hypersensitivity reaction to thienopyridines: prasugrel-induced fever and hepatitis resolved after switching to clopidogrel.
    Fernández-Ruiz M; Carbonell-Porras A; García-Reyne A; López-Medrano F
    Rev Esp Cardiol (Engl Ed); 2012 Aug; 65(8):773-4. PubMed ID: 22377199
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.